Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma in 132 Chinese patients. Issue 2 (14th December 2015)

• Record Type: Journal Article
• Authors: Su, Ting‐Shi; Liang, Ping; Lu, Huan‐Zhen; Liang, Jian; Gao, Ying‐Chuan; Zhou, Ying; Huang, Yong; Tang, Min‐Yang; Liang, Jian‐Ning
• Is Part Of: Journal of surgical oncology. Volume 113:Issue 2(2016)
• Page Start: 181
• Page End: 187
• Publication Date: 2015-12-14
• Subjects: hepatocellular carcinoma -- small HCC -- stereotactic body radiation therapy -- CyberKnife -- radiotherapy; Cancer -- Surgery -- Periodicals; Neoplasms -- Periodicals; 616
• DOI: 10.1002/jso.24128
• Languages: English
• ISSNs: 0022-4790

Abstract

Abstract : Aim: To evaluate the efficacy of stereotactic body radiation therapy (SBRT) in small hepatocellular carcinoma (HCC) patients. Methods: From March 2009 to April 2015, we treated 132 small HCC patients with SBRT. Eligibility criteria included longest tumor diameter ≤5.0 cm; Child‐Turcotte‐Pugh (CTP) Class A or B; unfeasible, difficult or refusal to undergo other surgery or percutaneous ablative therapies; and tumor recurrence after other local treatment. The dose of 42–46 Gy in 3–5 fractions and 28–30 Gy in 1 fraction was prescribed. Results: Of the treated patients, 114 were classified as CTP A and 18 as CTP B. Median tumor size was range 1.1–5.0 cm. The local control rate at 1 years was 90.9%. OS at 1, 3, and 5 years was 94.1%, 73.5%, and 64.3%, respectively. PFS at 1, 3, and 5 years was 82.7%, 58.3%, and 36.4%, respectively. Hepatic toxicity grade ≥3 was observed in 11 patients. Multivariate analysis revealed that CTP B was associated with worse OS ( P < 0.001) and multiple nodules were associated with worse PFS ( P = 0.001). Conclusions: SBRT is a promising alternative treatment for patients with primary or recurrent small HCC who are unsuitable for surgical resection or local ablative therapy. J. Surg. Oncol. 2016;113:181–187 . © 2015 Wiley Periodicals, Inc.